Posted by Michael Wonder on 06 May 2020
Antabio receives FDA qualified infectious disease product designation for MEM-ANT3310, a novel broad-spectrum combination therapy targeting WHO’s priority pathogens
6 May 2020 - QIDP is granted to Antabio’s MEM-ANT3310 for major hospital indications including nosocomial pneumonia.
Antabio announced today that the U.S. FDA has granted qualified infectious disease product designation to Antabio’s MEM-ANT3310, a combination of meropenem (MEM) and the novel broad-spectrum serine beta-lactamase inhibitor ANT3310.
QIDP was granted to MEM-ANT3310 for the treatment of complicated urinary tract infections, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia and complicated intra-abdominal infections.
